Mr. Smith will be responsible for overseeing all financial operations and investor relations activities for the Company.
| WIXOM, Mich., Nov. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the “Company” or “Rockwell Medical”) today announced that Angus Smith has been appointed as Chief Financial Officer of the Company, effective at the end of November 2018. Mr. Smith will be responsible for overseeing all financial operations and investor relations activities for the Company. Mr. Smith will join Rockwell Medical from Pernix Therapeutics, a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, where he currently serves as Senior Vice President, Chief Business Officer and Principal Financial Officer. Prior to this role, he served as Vice President, Business Development & Strategic Planning, and as Vice President, M&A and Corporate Finance. Prior to joining Pernix, Mr. Smith worked in healthcare investment banking, most recently serving as a Director in the Healthcare Investment Banking Group at Cantor Fitzgerald. During his nearly decade-long investment banking tenure, Mr. Smith focused on providing strategic and financial advice to specialty pharmaceutical and healthcare companies. He holds a B.A. in Mathematical Economics from Colgate University. “After conducting a thorough search process, we are very pleased to announce Angus’ appointment as CFO of Rockwell Medical,” said Stuart Paul, President and Chief Executive Officer of Rockwell Medical. “Angus’ deep financial expertise, along with his background advising specialty pharmaceutical and healthcare companies, are a great fit for Rockwell Medical. He brings a diverse knowledge base to the CFO role given his experience with debt and equity financings, mergers and acquisitions, licensing agreements, joint ventures and strategic partnerships. We are confident he will be an asset to our leadership team as we continue our work to drive financial and operational performance for the benefit of our shareholders.” Mr. Smith said, “I am honored to be named Rockwell Medical’s next CFO at this pivotal time in the Company’s history. I look forward to drawing on my background and working with Stuart and the entire Rockwell Medical team to achieve results for our shareholders.” Ignite Search Partners, a leading executive recruiting firm, assisted with the search process. The Company will file a Form 8-K with the Securities and Exchange Commission regarding this appointment. About Rockwell Medical, Inc. Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical’s anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell’s FDA approved generic drug Calcitriol (active vitamin D) is for treating secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates (used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream) to dialysis providers and distributors in the U.S. and abroad. Please visit www.rockwellmed.com for more information. Forward-Looking Statement Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to bring to market Triferic, IV Triferic and Calcitriol. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: statements about the timing and success of our planned NDA submission for IV Triferic; the potential market opportunity for IV Triferic and other Rockwell products; pricing and reimbursement status for IV Triferic, Triferic and other Rockwell products; liquidity and capital resources; and plans relating to the commercialization of Triferic and Calcitriol. Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Contacts
SOURCE Rockwell Medical, Inc. |
Company Codes: NASDAQ-NMS:RMTI |
View original content:
